pharma · Primary Mitochondrial Myopathy · Advanced Solid Tumors, Advanced Breast Cancer · OKUR
OnKure Therapeutics
OnKure Therapeutics clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Boulder, USA
- Founded
- 2011
- Employees
- 42
- Programs
- 8
- Drugs
- 4
- Patents
- 7
OnKure Therapeutics projects
8 ClinicalTrials.gov programs sponsored by OnKure Therapeutics.
OnKure Therapeutics has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
REN001
OnKure Therapeutics
Primary Mitochondrial Myopathy
2 trials -
Mavodelpar
OnKure Therapeutics
Primary Mitochondrial Myopathy
1 trial -
OKI-179 + binimetinib
OnKure Therapeutics
RAS Mutation
1 trial -
Low Dose REN001
OnKure Therapeutics
Fatty Acid Oxidation Disorders
1 trial -
OKI-179
OnKure Therapeutics
Advanced Solid Tumors
1 trial -
OKI-219
OnKure Therapeutics
Advanced Cancer
1 trial -
OKI-219-101
OnKure Therapeutics
Advanced Solid Tumors, Advanced Breast Cancer
1 trial -
REN001
OnKure Therapeutics
McArdle Disease
1 trial
Frequently asked questions
How many clinical projects does OnKure Therapeutics have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.